TITLE

Effects of β-Blockers on Neurohormonal Activation in Patients with Congestive Heart Failure

AUTHOR(S)
Baran, D.; Horn, E.M.; Hryniewicz, K.; Katz, S.D.
PUB. DATE
November 2000
SOURCE
Drugs;Nov2000, Vol. 60 Issue 5, p997
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The effect of β-adrenoceptor antagonists (β-blockers) on neurohormonal activation in patients with congestive heart failure has been the subject of study in numerous small clinical trials. Short term therapy with β-blockers is associated with a variable acute neurohormonal response which may be determined by the pharmacology of the agent under study and the baseline characteristics of the patient population. Long term therapy with β-blockers devoid of intrinsic sympathomimetic activity (partial agonist activity) is associated with evidence of decreased plasma markers of activation of the sympathetic nervous system, the renin-angiotensin system, and endothelin-1. β-Selective and nonselective β-blockers appear to be associated with evidence of decreased neurohormonal activation, with differential effects on β-adrenoceptor density. Agents with partial agonist activity appear to differ from pure antagonists, with some studies reporting evidence of increased neurohormonal activation. The mechanisms by which β-blockers reduce neurohormonal activation and the clinical relevance of changes in adrenergic function to their use in the treatment of heart failure require further investigation.
ACCESSION #
9593253

 

Related Articles

  • Do Cardioselective β-Adrenoceptor Antagonists Reduce Mortality in Diabetic Patients with Congestive Heart Failure? Subramanian, Usha; Kamalesh, Masoor; Temkit, M’Hamed; Eckert, George J.; Sawada, Stephen // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 4, p231 

    Background: The relative benefits of cardioselective β-adrenoceptor antagonists (CSB) among patients with congestive heart failure (CHF) and diabetes mellitus are not firmly established. Objective: To determine whether diabetic patients with CHF accrue the same mortality benefit from CSB...

  • Relax That Heart. Gorman, Christine // Time International (South Pacific Edition);1/18/1999, Issue 3, p62 

    Focuses on the availability of new beta-blocker drugs to treat congestive heart failure and hypertension. The increased cases of congestive heart failure due to doctors' success in saving heart-attack patients and an aging population; Research which showed benefits of treating patients with...

  • Relax That Heart. Gorman, Christine // Time;1/18/1999, Vol. 153 Issue 2, p94 

    Focuses on the availability of new beta-blocker drugs to treat congestive heart failure and hypertension. The increased cases of congestive heart failure due to doctors' success in saving heart-attack patients and an aging population; Research which showed benefits of treating patients with...

  • Beta blockers vs. newer glaucoma agents: How do the pieces fit? Mundorf, Thomas K. // Ophthalmology Times;09/01/97 Supplement, Vol. 22 Issue 17, p2 

    Presents a transcript of the roundtable discussion on the changing role of beta blockers as first line therapy in the management of open-angle glaucoma at the 1997 meeting of the Association for Research in Vision and Ophthalmology. Improvements on nonselective beta blockers; Safeness of the...

  • To beta-block or not? Karmali, Shamir; Mistry, Ravin; Walker, David // British Journal of Hospital Medicine (17508460);Jun2015, Vol. 76 Issue 6, p370 

    The article discusses the use of perioperative beta-blockers in patients who are at risk for coronary artery disease. Topics covered include the conduct of a study which revealed a decline in perioperative cardiac ischaemic events and mortality in patients who receive atenolol, the release of a...

  • Heart Failure. Mann, Douglas L. // Texas Heart Institute Journal;2006, Vol. 33 Issue 2, p201 

    The article examines some heart failure therapies. There are three categories of therapies in heart failure and these are cardiorenal agents or diuretics, cardiocirculatory agents or inotropics and vasodilators and neurohormonal agents that includes angiotensin-converting enzyme inhibitors,...

  • Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis. Sinclair, D.J.M. // British Medical Journal;1/20/1979, Vol. 1 Issue 6157, p168 

    Presents the treatment for hypertension and angina pectoris by beta-adrenergic blockade. Effects of metoprolol and propranolol on the airways of patients; Emphasis on the dosage of the drugs administered; Discussions on the sympathetic activity in patients.

  • Beta-blockers after MI: Seriously underused. Pinkowish, Mary Desmond // Patient Care;2/28/1997, Vol. 31 Issue 4, p29 

    Cites the findings of a study on the use of beta-blockers in postmyocardial infarction therapy in the United States. Beneficial effects of beta-blockers in postmyocardial infarction therapy; Underusage of beta-blockers in postmyocardial infarction therapy; Recommendation to avoid adverse...

  • Treatment of thyrotoxic storm with intravenous administration of propranolol. Das, Gopal; Krieger, Michael; Das, G; Krieger, M // Annals of Internal Medicine;May69, Vol. 70 Issue 5, p985 

    Describes the case of a thyrotoxic storm which was refractory to conventional therapy but responded immediately to beta adrenergic blockade by means of intravenous administration of propranolol. Medical history of the patient studied; Symptoms reported by the patient; Factor attributed to the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics